Parkinson’s disease (PD) is a long-term degenerative disorder of the central nervous system that primarily affects the motor system. There is currently no cure for PD, but treatments are available to help relieve symptoms and maintain quality of life. PD affects more than one million people in the U.S. and 10 million worldwide. In the European Union, the prevalence is similar to that of the United States, being approximately 1.2 million people, and its incidence is expected to triple by 2050. In the United States, the economic burden of PD is at least USD 14.4 billion per year, with USD 8.1 billion in medical expenses and USD 6.3 billion in indirect costs attributed to the disease.

It is important to note that although there are some treatment alternatives, there is currently no effective medical alternative available and no specific diagnostic test, thus making this disease a complex and sometimes lengthy process.

CIDEM-113, also known as JM-20, is a small, hybrid molecular chemical entity with multiple cellular and subcellular targets. CIDEM-113 was designed and developed by the Center for Pharmaceutical Research and Development (CIDEM) and the University of Havana in Cuba. The CIDEM-113 project is currently completing the preclinical phase to initiate clinical development.